Pipeline Programs↗
Distinct drugs in development (Preclinical–Phase 3)
Indications↗
Distinct diseases across all programs
Clinical Trials↗
All sponsored trials (all statuses)
Pipeline
By Phase
32 drugs in development
By Therapeutic Area
top 6
R&D Momentum
95/100
Pipeline Velocity
74/100
Trial Completion Rate
76/100
Pipeline Concentration
13/100
Pipeline Freshness
71/100
Strategic Signals
Activity
Last 14 days
Mechanistic Studies of Psilocybin in Headache Disorders
Neural and Behavioral Correlates of Live Face-to-Face Interactions
Computationally, Electrophysiologically, and Qualitatively Characterizing Serotonergic Psychedelics; Transdiagnostic Therapeutic and Pro-Psychotic Effects
A Unified Protocol to Address Sexual Minority Women's Minority Stress, Mental Health and Hazardous Drinking
Exploration of Synaptotrophic Effects of Psilocybin in Opioid Use Disorder (OUD)
Details
Company Overview
—
Mkt Cap
—
Revenue
—
Cash
Pipeline
Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)